Pharmac is proposing to widen access to a medicine used in the treatment of chronic heart failure.
The medicine, empagliflozin, would be available to people who have chronic heart failure with reduced ejection fraction – about half of all people with chronic heart failure.
Pharmac director of pharmaceuticals Geraldine MacGibbon says empagliflozin is a medicine that can give people more time with their loved ones and lessens the time spent in hospital.
The Government has recently announced its plan to modernise the regulation of medicines and medical devices by replacing the Medicines Act 1981 with a new Medical Products Bill (Bill). Read...
Proceedings of the Health New Zealand Te Whatu Ora, University of Auckland and AUT Collaborative Research Symposium 2024. Read...
Despite three decades of policy initiatives to improve integration of health care, delivery of health care in New Zealand remains fragmented, and health inequities persist for Māori and other high priority populations. Read...
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI